Evidence map›Paper›PMID 37568819›Full record

ArticleCancers2023

Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors.

Maria A Lopez-Olivo, Johncy J Kachira, Maryam Buni, Sang Taek Kim, Huifang Lu, Jean H Tayar, Gabrielle F Duhon, Juan I Ruiz, Clifton O Bingham, Cassandra Calabrese and 2 more

Abstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Patient Voices in Rheumatic Immune-related Adverse Events.Rheumatic diseases clinics of North America · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maria A Lopez-OlivoDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-5165-8393
Johncy J KachiraDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-0544-9491
Maryam BuniSection of Rheumatology and Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sang Taek KimSection of Rheumatology and Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Huifang LuSection of Rheumatology and Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jean H TayarSection of Rheumatology and Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Gabrielle F DuhonDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Juan I RuizDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Clifton O BinghamDivision of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD 21224, USA.
Cassandra CalabreseCleveland Clinic Foundation, Cleveland Heights, OH 44195, USA.
Robert J VolkDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Maria E Suarez-AlmazorDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Improving decision-making in patients with resectable melanoma and pre-existing autoimmune disease considering immune checkpoint inhibitionK08CA237619 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOPEZ-OLIVO, MARIA DE LOS ANGELES · 2020 to 2024
$938k
Characterization of Altered Immunity in Patients with Inflammatory Arthritis Induced by Immune Checkpoint Inhibitor TherapyK08AR079587 · NIAMS · YALE UNIVERSITY · PI KIM, SANG TAEK · 2021 to 2025
$863k
NCI NIH HHS CA237619NCI NIH HHS K08 CA237619NCI NIH HHS P30 CA016672NCI NIH HHS P30CA016672NIAMS NIH HHS K08 AR079587
6 · The paper itself

Abstract

Patients with pre-existing autoimmune disorders and cancer considering immune checkpoint inhibitors (ICIs) need to receive balanced information about the benefits and risk of developing immune-related adverse events (irAEs) and flare-ups of their autoimmune disease. To assess the learning needs of patients with cancer and pre-existing autoimmune disease regarding ICI treatment, we interviewed 29 patients with autoimmune disease and cancer from a comprehensive cancer center, of whom 20 had received ICI and 9 were candidates to receive ICI at a US Cancer Center. In-depth semi-structured interviews were conducted from August 2021 and January 2022. Interviewee's opinions and preferences about content and information delivery methods were collected. We recorded and transcribed interviews and analyzed them using thematic analysis. Half of the participants were female, and their median (SD) age was 62.9 (±10.9) years. The identified health information needs included the following: (1) information on irAEs and autoimmune disease flare-ups; (2) benefits of ICI; (3) ICI mechanism in the context of autoimmune disease; (4) management of flare-ups; (5) reasons for stopping or modifying cancer or autoimmune disease treatment; (6) likelihood of autoimmune disease progression or organ damage; and (7) lifestyle changes that could help avoid irAEs. Patients who had received ICI and those who had not yet received treatment reported similar needs, although patients who had received ICI had more questions about cancer treatment modifications. Patients also expressed the need to better understand when to contact their provider and how to share information with multiple providers. Most patients wanted to receive information in visual formats for review at home and at their own pace. Patients expressed interest in having educational tools to facilitate shared decision-making with their physicians, and they identified several areas of health information concerning therapy with ICI. They also highlighted the importance of communication among their various providers.

Indexed as

autoimmune diseasesimmunotherapypatient educationqualitative interviews

Identifiers

PMID37568819
PMCPMC10416973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.